WallStSmart

Precision BioSciences Inc (DTIL)vsModerna Inc (MRNA)

VS
⚡

Smart Verdict

WallStSmart Research — data-driven comparison

Moderna Inc generates 5506% more annual revenue ($2.52B vs $45.04M). DTIL leads profitability with a -85.6% profit margin vs -110.5%. MRNA earns a higher WallStSmart Score of 31/100 (F).

DTIL

Avoid

26

out of 100

Grade: F

Growth: 7.3Profit: 2.0Value: 6.3Quality: 5.5
Piotroski: 2/9Altman Z: -3.79

MRNA

Avoid

31

out of 100

Grade: F

Growth: 4.0Profit: 3.0Value: 6.7Quality: 7.0
Piotroski: 3/9Altman Z: 2.09
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

DTILUndervalued (+56.6%)

Margin of Safety

+56.6%

Fair Value

$9.38

Current Price

$7.28

$2.10 discount

UndervaluedFair: $9.38Overvalued
MRNAUndervalued (+73.1%)

Margin of Safety

+73.1%

Fair Value

$150.76

Current Price

$215.27

$64.51 discount

UndervaluedFair: $150.76Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

DTIL1 strengths · Avg: 10.0/10
Revenue GrowthGrowth
37272.0%10/10

Revenue surging 37272.0% year-over-year

MRNA2 strengths · Avg: 8.5/10
Market CapQuality
$101.49B9/10

Large-cap with strong market position

Revenue GrowthGrowth
29.2%8/10

Revenue surging 29.2% year-over-year

Areas to Watch

DTIL4 concerns · Avg: 3.5/10
P/E RatioValuation
30.3x4/10

Premium valuation, high expectations priced in

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$288.76M3/10

Smaller company, higher risk/reward

Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

MRNA4 concerns · Avg: 2.8/10
Price/BookValuation
12.7x4/10

Trading at 12.7x book value

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Return on EquityProfitability
-40.8%2/10

ROE of -40.8% — below average capital efficiency

EPS GrowthGrowth
-85.1%2/10

Earnings declined 85.1%

Comparative Analysis Report

WallStSmart Research

Bull Case : DTIL

The strongest argument for DTIL centers on Revenue Growth. Revenue growth of 37272.0% demonstrates continued momentum.

Bull Case : MRNA

The strongest argument for MRNA centers on Market Cap, Revenue Growth. Revenue growth of 29.2% demonstrates continued momentum.

Bear Case : DTIL

The primary concerns for DTIL are P/E Ratio, EPS Growth, Market Cap.

Bear Case : MRNA

The primary concerns for MRNA are Price/Book, Piotroski F-Score, Return on Equity.

Key Dynamics to Monitor

DTIL profiles as a hypergrowth stock while MRNA is a growth play — different risk/reward profiles.

DTIL carries more volatility with a beta of 1.35 — expect wider price swings.

DTIL is growing revenue faster at 37272.0% — sustainability is the question.

DTIL generates stronger free cash flow (-15M), providing more financial flexibility.

Bottom Line

MRNA scores higher overall (31/100 vs 26/100) and 29.2% revenue growth. DTIL offers better value entry with a 56.6% margin of safety. Both earn "Avoid" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Precision BioSciences Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Precision BioSciences, Inc., a genome editing company, develops therapeutic products in the United States. The company is headquartered in Durham, North Carolina.

Visit Website →

Moderna Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Moderna, Inc., a biotechnology company, develops messenger RNA-based vaccines and therapies for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and autoimmune diseases. The company is headquartered in Cambridge, Massachusetts.

Want to dig deeper into these stocks?